Halozyme to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.

The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.

News Market Reaction

-0.51%

1 alert

-0.51% News Effect

On the day this news was published, HALO declined 0.51%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences. 

Details on the Company's participation are as follows:

Event:				2025 Wells Fargo Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Thursday, September 4, 2025
Presentation Time:				10:30am PT / 1:30pm ET
Location:				Boston, MA

Event:				Morgan Stanley 23rd Annual Global Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Date:				Monday, September 8, 2025
Presentation Time:				4:45am PT / 7:45am ET
Location:				New York, NY
Event:				H.C. Wainwright 27th Annual Global Investment Conference
Format:				1x1 Meetings
Date:				Tuesday, September 9, 2025
Location:				New York, NY

A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302540470.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme (HALO) presenting at the Wells Fargo Healthcare Conference 2025?

Halozyme will present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 10:30am PT / 1:30pm ET in Boston, MA.

What time is Halozyme's presentation at the Morgan Stanley Healthcare Conference 2025?

Halozyme will present at the Morgan Stanley Conference on Monday, September 8, 2025 at 4:45am PT / 7:45am ET in New York, NY.

Who will represent Halozyme at the 2025 investor conferences?

Dr. Helen Torley, President and CEO, and Tram Bui, VP of Investor Relations and Corporate Communications, will represent Halozyme.

How can investors access Halozyme's conference presentations?

Investors can access live audio webcasts of the presentations in the Investor Relations section of Halozyme's website. Replays will be available for 90 days following each conference.